OPKO Health, Inc. Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31)
OPKO Health, Inc. (OPK) had Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) of $68.90 million as of 2013-06-30, per its 10-Q filed 2013-08-09.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionContingentConsiderationAtFairValue · last filed 2013-08-09
- 2013-06-30: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $68.90M.
- 2013-03-31: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $66.30M.
- 2012-12-31: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $20.00M.
- 2012-09-30: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $21.90M.
| Period end | Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) |
|---|---|
| 2013-06-30 | $68.90M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $66.30M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $20.00M 10-Q · filed 2013-08-09 |
| 2012-09-30 | $21.90M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $20.10M 10-Q · filed 2012-08-09 |
| 2011-12-31 | $100.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |